Kleem Chaudhary
Corporate Officer/Principal bei CHECKMATE PHARMACEUTICALS, INC.
Profil
Kleem Chaudhary is currently the President, Chief Executive Officer & Director at Hyku Biosciences, Inc. He is also the Chief Business Officer at Checkmate Pharmaceuticals, Inc. and the Chief Operating Officer at Redona Therapeutics, Inc. Previously, Dr. Chaudhary worked as the Director-Oncology Division at Novartis AG from 2009 to 2016.
He then served as the Senior Director-Business Development & Licensing at Takeda Pharmaceutical Co., Ltd.
from 2016 to 2018.
After that, he was the Head-Business Development & Licensing at Biogen, Inc. from 2018 to 2019.
Dr. Chaudhary holds a doctorate degree from The University of North Carolina at Chapel Hill and an undergraduate degree from The University of Winnipeg.
Aktive Positionen von Kleem Chaudhary
| Unternehmen | Position | Beginn |
|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2019 |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Geschäftsführer | - |
Ehemalige bekannte Positionen von Kleem Chaudhary
| Unternehmen | Position | Ende |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01.10.2019 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01.01.2018 |
| NOVARTIS AG | Corporate Officer/Principal | 01.05.2016 |
Ausbildung von Kleem Chaudhary
| The University of Winnipeg | Undergraduate Degree |
| The University of North Carolina at Chapel Hill | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| NOVARTIS AG | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Redona Therapeutics, Inc.
Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Health Technology |
